Friday, October 2, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Press releaseGlobeNewswire· March 2, 2026

Agora, Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results

View original at globenewswire.com

Agora, Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results SANTA CLARA, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Agora, Inc…

Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Company expects Q1 2026 total revenues between $36 million and $37 million, representing 8.1% to 11.1% year-over-year growth
80% confidence
Company achieved fifth consecutive quarter of GAAP profitability, marking first full year of profitability since 2018, driven by sustained double-digit revenue growth
80% confidence
Platform's scalability was validated during Super Bowl live shopping event with nearly 600,000 peak concurrent viewers and sub-second latency
80% confidence
Company started 2026 with strong reception of conversational AI solutions for Physical AI at CES, highlighted by leading vision and motion control capabilities
80% confidence
Company remains focused on driving revenue growth and advancing conversational AI innovation throughout 2026
80% confidence
Conversational AI engine usage has more than doubled each quarter since March 2025 launch
80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts

AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.

Our read on the data ›

Signals we're tracking

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,985

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,985 facts checked against source5,327 source documents archived

Query this data → isubstrate.com